Amgen receives CHMP positive opinion to expand use of BLINCYTO® (Blinatumomab)
Amgen announced the CHMP of the EMA has adopted a positive opinion to expand the current indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor ALL in first or second complete remission. November 16, 2018